29 Oct, 2018, 08:00 ET
OAKLAND, Calif., Oct. 29, 2018 /PRNewswire/ -- Modis Therapeutics announced today that Matthew R. Patterson, co-founder and Chief Executive Officer of Audentes Therapeutics, has joined Modis' Board of Directors.
Mr. Patterson co-founded Audentes Therapeutics in 2012 and has served as the company's Chief Executive Officer since its inception, leading Audentes from concept stage to late clinical stage with an innovative platform and promising pipeline of gene therapy product candidates. He has more than 25 years of experience in the research, development, and commercialization of novel treatments for rare diseases and has held positions of senior management in both private and public biotechnology companies. Previously Mr. Patterson worked for Genzyme Corporation, BioMarin Pharmaceutical, and Amicus Therapeutics. Prior to Audentes he was an Entrepreneur-In-Residence with OrbiMed. Mr. Patterson also currently serves as Chairman of the Alliance for Regenerative Medicine (ARM) and is a member of the Board of Directors for Homology Medicines.
"We are pleased to welcome Matt to the Modis Board of Directors," said Joshua Grass, Chief Executive Officer of Modis Therapeutics. "We believe that his operational expertise and extensive management experience complement the current Board and that his knowledge of rare disease drug development and his success leading Audentes through tremendous growth will be invaluable to Modis as the company grows."
"I am excited to join the Modis Board of Directors," said Mr. Patterson. "I believe the company is exceptionally well positioned with an experienced management team, strong financial backers, and a lead program with compelling clinical data. I look forward to working with the team at Modis to bring important new therapies to patients with rare diseases."
About Modis Therapeutics
Modis Therapeutics, Inc. is a biopharmaceutical company focused on developing disease-modifying therapies for rare genetic diseases with high unmet medical need. It was formed in 2016 through a collaboration with academic experts in mitochondrial biology. The company's lead program (MT1621) is in clinical development for thymidine kinase 2 deficiency (TK2d), an inherited mitochondrial disease. Modis Therapeutics is headquartered in Oakland, CA, with offices in New York City. For more information please visit www.modistx.com.
VP Finance & Administration
Modis Therapeutics, Inc.
SOURCE Modis Therapeutics
Share this article